1\) Treatment in Peking University People's Hospital for radical resection of breast cancer and had hospitalization records;
2\) Postoperative pathology confirmed invasive breast cancer, and the pathological stage was T1a-b (T ≤ 1cm), N0, HER2 positive, with high-risk factors (G3, or hormone receptor negative); Or the pathological stage is T1c (1cm \< T ≤ 2cm), N0, and there are no high-risk factors (G1/G2, hormone receptor positive);
3)Signed an agreement to participate in the PKUPH Breast Disease Cohort study at Peking University People's Hospital.
You may not be if
1\) Lack of clinical pathological data (such as imaging data, pathological data);
2\) Preoperative neoadjuvant therapy;
3\) Patients with metastatic breast cancer or bilateral breast cancer;
4\) Failed to undergo curative surgery.
Clareo Health | Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
